Company intelligence / Profile preview

BioJuven

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

BioJuven is an early-stage biotechnology company focused on the field of rejuvenation biotechnology and longevity. The company specializes in developing therapies aimed at reversing the aging process at the cellular level, primarily through epigenetic reprogramming and the modulation of cellular senescence. By leveraging advanced genetic and molecular tools, BioJuven seeks to address a wide range of age-related diseases and extend healthy human lifespan. The company's research is centered on identifying and targeting key drivers of biological aging to restore youthful cellular function.

Therapeutic areas: Other
Modalities: Gene therapySmall moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on BioJuven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioJuven.

Explore the full profile